Effective August 1, 2022, the Board of Directors of Zhong Yuan Bio-Technology Holdings Limited accepted the resignations of Lingxiao Dai and Jen-Chuan Yeh as non-executive independent members of the Board of Directors of the Company. The Company simultaneously accepted the resignations of Ms. Dai and Mr. Yeh as the two members of the audit committee, and further accepted the resignation of Ms. Dai as the chairman of the Audit Committee. Effective August 1, 2022, the Board of Directors accepted the consents of the following individuals to serve as non- executive independent members of the Board of Directors, and authorized and approved their appointments: (i) Ms. Daphne Huang; (ii) Mr. Chi Wai (Gabriel) Tse; and (iii) Dr. Shuo Dong.

Effective August 1, 2022, the Board of Directors further authorized and appointed Ms. Huang, Mr. Tse and Dr. Dong as members of the Audit Committee, the Nomination Committee and the Compensation Committee. Each of the members of the Audit Committee, the Nomination Committee and the Compensation Committee satisfies the “independence” requirements of the Nasdaq listing rules and meets theindependence standards under Rule 10A-3 under the Securities Exchange Act of 1934, as amended (“Exchange Act”). Ms. Huang will be the chairman of the Audit Committee; Mr. Tse will be the chairman of the Compensation Committee; Dr. Dong will be the chairman of the Nomination Committee.

Our Board of Directors has also determined that Ms. Huang possesses accounting or related financial management experience that qualifies her as an “audit committee financial expert” as defined by the rules and regulations of the SEC. Daphne Huang. Ms. Huang, age 51, was appointed as an independent non-executive director effective August 1, 2022.

She will be responsible for providing independent judgment on issues of strategy, policy, performance, accountability, resources, key appointments and standard of conduct. Ms. Huang is a member of the Audit, Compensation and Nomination Committees.She is also Chairman of the Audit Committee. Ms. Huang has more than 20 years of senior executive experience in finance within which more than ten years of experience as chief financial officer of global manufacturing, pharmaceutical, and technology sectors companies.

Since July 2022, Ms. Huang has been chief financial officer of Gorilla Technology Group Inc., a NASDAQ listed edge AI company. From August 2021 to July 2022, she was chief financial officer of GoFor Industries Inc., an IT platform logistics company with operations in Canada and the U.S. From April 2020 through August 2021, she was the chief financial officer and chief accounting officer for Taro Pharmaceutical Industries Ltd., a research-based multinational pharmaceutical company with operations in the U.S., Canada and Israel. Prior to her career as chief financial officer, Ms. Huang held positions of increasing responsibility in the financial service and debt capital markets sectors working for such companies as PriceWaterhouseCoopers, FleetBoston, GE Capital and HSBC.

Ms. Huang earned a Bachelor of Business Administration in Accounting from Baruch College, City University of New York, graduating cum laude in August 1995. She also earned a Master of Business Administration in Finance/Management/International Business from the Leonard N. Stern School of Business at New York University in May 2000. Chi Wai (Gabriel) Tse.